[go: up one dir, main page]

WO2022032360A1 - Composition à base d'huiles végétales utilisée comme substitut de lanoline - Google Patents

Composition à base d'huiles végétales utilisée comme substitut de lanoline Download PDF

Info

Publication number
WO2022032360A1
WO2022032360A1 PCT/BR2020/050313 BR2020050313W WO2022032360A1 WO 2022032360 A1 WO2022032360 A1 WO 2022032360A1 BR 2020050313 W BR2020050313 W BR 2020050313W WO 2022032360 A1 WO2022032360 A1 WO 2022032360A1
Authority
WO
WIPO (PCT)
Prior art keywords
lanolin
oil
composition based
mass
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2020/050313
Other languages
English (en)
Portuguese (pt)
Inventor
Angel DACHS YAGODA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maian Industria De Produtos Quimicos Ltda
Original Assignee
Maian Industria De Produtos Quimicos Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maian Industria De Produtos Quimicos Ltda filed Critical Maian Industria De Produtos Quimicos Ltda
Priority to PCT/BR2020/050313 priority Critical patent/WO2022032360A1/fr
Priority to BR112023002610A priority patent/BR112023002610A2/pt
Publication of WO2022032360A1 publication Critical patent/WO2022032360A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention refers to a composition based on vegetable oils with application in the cosmetic or pharmaceutical industry, as a substitute for lanolin. Particularly in the pharmaceutical industry, the composition has healing properties.
  • Lanolin is the fat in wool that is manufactured from the sebaceous secretions of sheep's fat. It is a mixture of sterols and long-chain fatty alcohols. This mixture sometimes contains other substances (nickel, chromium, copper, etc.) in the form of traces.
  • Lanolin is a natural product obtained from raw wool wax generated by textile improvers as a by-product of the process. During processing, the wool is washed with a mixture of soaps and detergents, generating a mixture of water, soaps and various types of impregnated impurities.
  • Lanolin is a wax consisting of a mixture of high molecular weight esters. These esters that compose it are the result of countless combinations between different types of alcohols and acids, making lanolin a unique material.
  • Lanolin is composed of esters whose acid fraction has a carbon chain ranging from C7 to C40 and the alcoholic fraction from C14 to C36. Therefore, the final combination of esters is very large, but the most important components are the hydroxy-esters from the combination of fatty acids with diols and sterols or fatty alcohols with hydroxy acids.
  • Lanolin is a chemical specialty with high added value and due to the volume demanded by the cosmetic and pharmaceutical industries, there is a need for many flocks of sheep to meet this demand. [009] Lanolin is a yellowish to gray semi-solid containing 25 to 30% water in its hydrated form and a yellow-brown semi-solid in its anhydrous form. Lanolin contains cholesteryl esters of higher fatty acids.
  • lanolin Due to its emollient, moisturizing, emulsifying properties and its ability to absorb water, lanolin is used as a component of pharmaceutical products, leather finishing compositions, soaps and detergents, face creams, facial tissues, hair compositions, suntan preparations and the like.
  • EP 0051148 teaches lanolin substitute product comprising short chain fatty acids and coconut fatty acid.
  • US 2005233015 A teaches lanolin substitute based on shea butter.
  • WO 2004065533 teaches lanolin substitutes that are obtained from saturated and/or unsaturated fatty acids, or their esters, or hydrocarbons, and may contain vegetable oils, which are subjected to heat treatment from 100 °C to 400 ° C, particularly between 230°C to 350°C.
  • DE 10143948 teaches a substitute product for lanolin based on polyisobutene, which may contain vegetable oils.
  • the present invention deals with a substitute product for lanolin that has advantages over products known to man in the art.
  • composition based on vegetable oils to replace lanolin was developed, which surprisingly has healing properties.
  • the composition comprises coconut oil, sunflower oil and soy lecithin.
  • composition based on vegetable oil substitutes for lanolin comprises:
  • coconut oil, coconut oil or coconut butter is a vegetable oil that contains about 90% of fatty acids extracted by pressing the pulp or core of coconuts (Cocos nucifera).
  • coconut fatty acid diethanolamides lauric alcohol derivatives such as sodium lauryl sulfate, corrosion inhibitors, sulfonated oil and several other products in the raw material industry for cosmetics.
  • _Coconut oil can be extracted through “dry” or “wet” processing. Dry processing requires the dough to be extracted from the shell and dried using fire, sunlight, or an oven to create copra. Copra is processed or dissolved with solvents, producing coconut oil and a pulp with high protein and fiber content. Pulp is generally used to feed ruminants, as it is not of sufficient quality by industrial standards. There is no process to extract the protein from the pulp.
  • the "wet” process uses raw coconut instead of copra, and the proteins present in the coconut create an emulsion of water and oil. The emulsion is then broken down by prolonged boiling, centrifugation or pretreatments including cold, heat, acids, salts, enzymes, electrolysis, shock waves, steam distillation, or some combination.
  • Another method for extracting coconut oil involves the enzymatic action of alpha-amylase, polygalacturonase and proteases in a diluted coconut paste.
  • Refined oil can be further processed into partially hydrogenated oil or hydrogenated oil, to increase its melting point.
  • virgin and refined oils melt at a temperature of 24°C
  • foods containing coconut oils tend to melt in hot climates. Therefore, a higher melting point is desirable in these climates.
  • the melting point of hydrogenated coconut oil varies between 36°C and 40°C.
  • the composition of refined coconut oil comprises C6 - C20 fatty acids, such as: caproic acid, caprylic acid, lauric acid, myristic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid and arachidic acid.
  • C6 - C20 fatty acids such as: caproic acid, caprylic acid, lauric acid, myristic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid and arachidic acid.
  • refined coconut oil extracted from the almond fruit of the oil palm Elaeis guineensis and subjected to the refining process has the fatty acid composition indicated in Table 1 below:
  • coconut fat is composed of lauric acid. In the human body, it is transformed into monolaurin, a monoglyceride of antibacterial, antiviral and antiprotozoal action, used by the body to destroy the lipid layer of various microorganisms.
  • the coconut oil according to the invention must have a maximum acidity Mg KOH/g of 0.1% measured by the AOCS Method Ca 5a-40.
  • the present invention deals with a composition that comprises, in relation to its total mass, from 50% to 85% by weight of coconut oil.
  • Refined coconut oil is preferably used.
  • composition also comprises in relation to its total mass from 8% to 26% of sunflower oil.
  • Sunflower oil is extracted from the seed of the Heüanthus annuus plant.
  • the sunflower Heüanthus annuus is an annual plant of the Asteraceae family, genus Heliantheae. The name is derived from the shape of its inflorescence.
  • Sunflower oil comprises C12 - C22 fatty acids such as: lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid (Omega 9), linoleic acid (Omega 6), linolenic acid (Omega 3), arachidic acid, eicosenoic acid, behenic acid, erucic acid and lignoceric acid, as indicated in Table 2 below:
  • sunflower oil is essentially made up of triacylglycerols (98 to 99%). It has a high content of unsaturated acids (about 83%), but a low content of linolenic acid ( ⁇ 0.2%). Sunflower oil is essentially rich in essential fatty acid (EFA) or linoleic acid.
  • EFA essential fatty acid
  • the sunflower oil according to the invention must have a maximum acidity Mg KOH/g of 2 measured by the AOCS Method Ca 5a-40 and comprise a C18:l grease chain from 75% to 90.7%.
  • composition according to the invention comprises, in relation to the total mass of the composition, 5% to 22% by mass of soy lecithin.
  • Lecithin is a phospholipid found naturally in foods of animal and vegetable origin, with egg yolk, soy and wheat germ being the main sources.
  • the main phospholipids present in marketed lecithin are phosphatidylcholine, phosphatidylinositol, phosphatidylethanolamine and phosphatidic acid (generally abbreviated as PC, PI, PE and PA, respectively).
  • the lecithin can be enzymatically hydrolyzed.
  • a portion of the phospholipids have a fatty acid removed by the action of a phospholipase.
  • Such phospholipids are referred to as lysophospholipids.
  • the most commonly used phospholipase for this purpose is called phospholipase A2, which removes the fatty acid at the sn-2 position.
  • Lecithins can also be modified by a process called fractionation, which consists of mixing the oil in an alcohol (usually ethanol). Some phospholipids have good solubility in ethanol (e.g. phosphatidylcholine), whereas other phospholipids are shown to be insoluble in the same solvent. The ethanol solution is then decanted and subjected to solvent evaporation in order to obtain a phosphatidylcholine-enriched lecithin fraction.
  • fractionation consists of mixing the oil in an alcohol (usually ethanol).
  • Some phospholipids have good solubility in ethanol (e.g. phosphatidylcholine), whereas other phospholipids are shown to be insoluble in the same solvent.
  • the ethanol solution is then decanted and subjected to solvent evaporation in order to obtain a phosphatidylcholine-enriched lecithin fraction.
  • the soy lecithin used according to the invention must have an acidity Mg KOH/g of at most 2 measured by the AOCS Ja 6-55 method.
  • the composition comprises, by mass in relation to the total mass of the composition, the following components:
  • the composition comprises, by mass in relation to the total mass of the composition, the following components:
  • the lanolin substitute composition according to the invention has healing properties and can be used in the pharmaceutical industry in products that require this property, such as ointments, plasters, etc.
  • the method of obtaining the composition involves the following steps:
  • the method of obtaining the composition involves the following steps:
  • a lanolin substitute composition according to the invention was reproduced comprising the components as indicated in Table 3 below:
  • composition indicated in example 1 was obtained through a protocol that involved the following steps:
  • the mixture was heated to a temperature of 50 °C, until the components became liquid (the temperature was not increased further as the carbon chains of the components could break);
  • human keratinocyte cells from the epidermis were used, maintained in culture with DMEM (Dulbecco's Modified Eagle's Medium) with the addition of supplements, in an oven at 37°C and 5% CO2 and manipulated inside a laminar flow hood. In passage 03 after thawing, the cells were distributed in 35mm plates.
  • DMEM Dulbecco's Modified Eagle's Medium
  • NV.12.02 showed complete closure of the sham wound, while the control group needed 48 hours to close the wound completely.
  • Figure 1 attached, brings the representative images of the respective groups and times.
  • Figure 2 and Table 4 demonstrate the percentage of wound closure according to time between groups, with 0% being considered at time 0h and 100% when it was not possible to identify the bottom of the plaque in the image.
  • Example 4 A lanolin substitute composition according to the invention was reproduced comprising the components as indicated in Table 5 below:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition à base d'huiles végétales trouvant une application dans l'industrie cosmétique ou pharmaceutique, utilisée comme substitut de lanoline. Particulièrement appropriée pour une application dans l'industrie pharmaceutique, la composition présente des propriétés cicatrisantes. La composition à base d'huiles végétales utilisée comme substitut de lanoline comprend les constituants suivants : (A) huile de noix de coco ; (b) huile de tournesol ; et (c) lécithine de soja.
PCT/BR2020/050313 2020-08-11 2020-08-11 Composition à base d'huiles végétales utilisée comme substitut de lanoline Ceased WO2022032360A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/BR2020/050313 WO2022032360A1 (fr) 2020-08-11 2020-08-11 Composition à base d'huiles végétales utilisée comme substitut de lanoline
BR112023002610A BR112023002610A2 (pt) 2020-08-11 2020-08-11 Composicão aditiva a base de óleos vegetais substituta de lanolina e método de obtenção

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2020/050313 WO2022032360A1 (fr) 2020-08-11 2020-08-11 Composition à base d'huiles végétales utilisée comme substitut de lanoline

Publications (1)

Publication Number Publication Date
WO2022032360A1 true WO2022032360A1 (fr) 2022-02-17

Family

ID=80246618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2020/050313 Ceased WO2022032360A1 (fr) 2020-08-11 2020-08-11 Composition à base d'huiles végétales utilisée comme substitut de lanoline

Country Status (2)

Country Link
BR (1) BR112023002610A2 (fr)
WO (1) WO2022032360A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161484A1 (en) * 2002-04-19 2004-08-19 Dee Gary J. Vegetable substitute for lanolin
US20050233015A1 (en) * 2002-05-27 2005-10-20 Staffan Norberg Lanolin substitute based on shea butter
WO2008150603A1 (fr) * 2007-06-01 2008-12-11 Elc Management Llc Compositions organiques aqueuses bien conserves
US20130224138A1 (en) * 2001-07-02 2013-08-29 Pierre Charlier De Chily Lanolin substitute, production method thereof and applications of same
US20190380350A1 (en) * 2016-01-21 2019-12-19 Penta 5 USA, LLC Topical mosquito control product with sunscreen
US20200171119A1 (en) * 2017-05-24 2020-06-04 Rachel Sarah Levine Composition for transdermal delivery of glutathione

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130224138A1 (en) * 2001-07-02 2013-08-29 Pierre Charlier De Chily Lanolin substitute, production method thereof and applications of same
US20040161484A1 (en) * 2002-04-19 2004-08-19 Dee Gary J. Vegetable substitute for lanolin
US20050233015A1 (en) * 2002-05-27 2005-10-20 Staffan Norberg Lanolin substitute based on shea butter
WO2008150603A1 (fr) * 2007-06-01 2008-12-11 Elc Management Llc Compositions organiques aqueuses bien conserves
US20190380350A1 (en) * 2016-01-21 2019-12-19 Penta 5 USA, LLC Topical mosquito control product with sunscreen
US20200171119A1 (en) * 2017-05-24 2020-06-04 Rachel Sarah Levine Composition for transdermal delivery of glutathione

Also Published As

Publication number Publication date
BR112023002610A2 (pt) 2023-04-04

Similar Documents

Publication Publication Date Title
Mititelu et al. Neacs, u
ES2864285T3 (es) Utilización de aguacates blandos enteros para obtener un aceite de aguacate rico en insaponificable
JP3502990B2 (ja) 植物由来の糖脂質、リゾホスホリピド、スフィンゴ脂質、セラミドを含有する化合物の分離方法
US8765105B2 (en) Human sebum mimetics derived from botanical sources and methods for making the same
BR112014017227B1 (pt) uso da semente do abacate para obtenção de um óleo de abacate enriquecido em alquil polióis e/ou derivados acetilados dos mesmos
ITMI20072081A1 (it) Esteri di glicerolo e loro impieghi in ambito cosmetico e farmaceutico
CN102266280A (zh) 精制鹿油在制备保湿化妆品中的应用
Gutierrez et al. Cottonseed oil composition and its application to skin health and personal care
Boadu et al. Chemical characterization of shea butter oil soap (Butyrospermum parkii G. Don)
US9289373B2 (en) Human sebum mimetics derived from botanical sources and methods for making the same
WO2022032360A1 (fr) Composition à base d'huiles végétales utilisée comme substitut de lanoline
Shahbaz et al. Beeswax
ES2864598T3 (es) Utilización de piel de aguacate para obtener un insaponificable de aguacate enriquecido en hidrocarburos alifáticos saturados y en esteroles
KR100826310B1 (ko) 화장료 조성물
CA2884331C (fr) Mimetiques du sebum humain derives de sources botaniques, et leurs procedes de fabrication
JP2014516940A (ja) 高不鹸化物およびその使用方法
US8765106B2 (en) Human sebum mimetics derived from botanical sources and methods for making the same
JP3671103B2 (ja) 化粧料
CN108542807A (zh) 一种具有保湿和抗皱功效的护手霜的制作方法
US20150004139A1 (en) Emollient Compounds Useful for Treating Dry Skin Conditions
da Costa Sanches et al. The use of vegetable oils to prevent skin aging
Krishna Coconut oil: science, technology, and applications
BR102017028213B1 (pt) Composição cosmética compreende óleo de licuri, uso da dita composição e método cosmético
Shahbaz et al. 10 Beeswax
CA2932042C (fr) Mimetiques de sebum humain derives de sources botaniques et procedes de fabrication desdits mimetiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20948899

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023002610

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 112023002610

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230210

122 Ep: pct application non-entry in european phase

Ref document number: 20948899

Country of ref document: EP

Kind code of ref document: A1